Long-Term Cancer and Mortality After Thymectomy

IF 4.3 2区 医学 Q1 CLINICAL NEUROLOGY
Shahar Shelly, Mor Ani, Christopher Klein, Yuebing Li, Henry Kaminski, Gil I. Wolfe, Keren Miron, Roni Ramon-Gonen
{"title":"Long-Term Cancer and Mortality After Thymectomy","authors":"Shahar Shelly,&nbsp;Mor Ani,&nbsp;Christopher Klein,&nbsp;Yuebing Li,&nbsp;Henry Kaminski,&nbsp;Gil I. Wolfe,&nbsp;Keren Miron,&nbsp;Roni Ramon-Gonen","doi":"10.1111/ene.70721","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Long-term health effects of thymectomy in adults remain uncertain. Previous reports suggested associations with increased mortality, cancer incidence, and autoimmune disease, although these findings may reflect differences in patient selection, surgical indication, or follow-up duration. We aimed to examine long-term outcomes following adult thymectomy.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We performed a propensity score-matched retrospective study of patients who underwent thymectomy or comparator cardiothoracic procedures, with follow-up extending to 10 years. Primary outcomes were all-cause mortality, new-onset malignancy, and autoimmune disease. Findings were compared with those reported in a recent study that has raised caution regarding thymic excision.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We identified 425 patients who underwent thymectomy and 5401 controls who underwent coronary artery bypass or valve surgery. After matching, 398 patients remained in each group. Thymectomy was not associated with increased mortality at 5 years (HR = 0.63; 95% CI, 0.38–1.04) or 10 years (HR = 0.78; 95% CI, 0.54–1.13). Excluding reclassified thymic cancers, 5-year extrathymic malignancy incidence was 2.3% versus 1.8% (<i>p</i> = 0.54); no significant differences were observed in immune-related disease. Mortality was higher among patients with thymic malignancy. Among MG patients, only one event occurred, precluding reliable estimation.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Thymectomy was not associated with excess mortality or malignancy at 10 years compared with matched cardiothoracic controls. Indication-stratified analyses within the thymectomy cohort showed higher mortality for thymic malignancy, with insufficient events to assess outcomes in MG patients. These findings do not support a generalized survival penalty from thymectomy, though caution is warranted for incidental thymic removal.</p>\n </section>\n </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"33 8","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.70721","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ene.70721","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Long-term health effects of thymectomy in adults remain uncertain. Previous reports suggested associations with increased mortality, cancer incidence, and autoimmune disease, although these findings may reflect differences in patient selection, surgical indication, or follow-up duration. We aimed to examine long-term outcomes following adult thymectomy.

Methods

We performed a propensity score-matched retrospective study of patients who underwent thymectomy or comparator cardiothoracic procedures, with follow-up extending to 10 years. Primary outcomes were all-cause mortality, new-onset malignancy, and autoimmune disease. Findings were compared with those reported in a recent study that has raised caution regarding thymic excision.

Results

We identified 425 patients who underwent thymectomy and 5401 controls who underwent coronary artery bypass or valve surgery. After matching, 398 patients remained in each group. Thymectomy was not associated with increased mortality at 5 years (HR = 0.63; 95% CI, 0.38–1.04) or 10 years (HR = 0.78; 95% CI, 0.54–1.13). Excluding reclassified thymic cancers, 5-year extrathymic malignancy incidence was 2.3% versus 1.8% (p = 0.54); no significant differences were observed in immune-related disease. Mortality was higher among patients with thymic malignancy. Among MG patients, only one event occurred, precluding reliable estimation.

Conclusions

Thymectomy was not associated with excess mortality or malignancy at 10 years compared with matched cardiothoracic controls. Indication-stratified analyses within the thymectomy cohort showed higher mortality for thymic malignancy, with insufficient events to assess outcomes in MG patients. These findings do not support a generalized survival penalty from thymectomy, though caution is warranted for incidental thymic removal.

Abstract Image

胸腺切除术后的长期癌症和死亡率
背景:成人胸腺切除术对健康的长期影响尚不确定。先前的报告显示与死亡率、癌症发病率和自身免疫性疾病增加有关,尽管这些发现可能反映了患者选择、手术指征或随访时间的差异。我们的目的是研究成人胸腺切除术后的长期结果。方法:我们对接受胸腺切除术或比较心胸手术的患者进行了倾向评分匹配的回顾性研究,随访时间延长至10年。主要结局是全因死亡率、新发恶性肿瘤和自身免疫性疾病。研究结果与最近的一项研究结果进行了比较,该研究对胸腺切除术提出了警告。结果我们确定了425例胸腺切除术患者和5401例接受冠状动脉搭桥术或瓣膜手术的对照组。配对后,每组保留398例患者。胸腺切除术与5年(HR = 0.63; 95% CI, 0.38-1.04)或10年(HR = 0.78; 95% CI, 0.54-1.13)死亡率增加无关。排除重新分类的胸腺癌,5年胸腺外恶性肿瘤发病率分别为2.3%和1.8% (p = 0.54);在免疫相关疾病方面没有观察到显著差异。胸腺恶性肿瘤患者的死亡率较高。在MG患者中,仅发生了一个事件,妨碍了可靠的估计。结论:与匹配的心胸组相比,胸腺切除术与10年死亡率或恶性肿瘤无关。胸腺切除术队列的适应症分层分析显示胸腺恶性肿瘤的死亡率更高,没有足够的事件来评估MG患者的预后。这些发现不支持胸腺切除术的普遍生存损失,尽管对偶然的胸腺切除需要谨慎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Journal of Neurology
European Journal of Neurology 医学-临床神经学
CiteScore
9.70
自引率
2.00%
发文量
418
审稿时长
1 months
期刊介绍: The European Journal of Neurology is the official journal of the European Academy of Neurology and covers all areas of clinical and basic research in neurology, including pre-clinical research of immediate translational value for new potential treatments. Emphasis is placed on major diseases of large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书